Skip to content

Arbutus Biopharma

US · ABUS #3365 by market cap Listed 2015
4.02 -0.05 -1.23%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:39

Price chart

Pre-market 4.01 -1.47%
After-hours 3.98 -1.00%
5.223.664.022026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on ABUS?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -10.0% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Short interest has risen to 10.0% of float.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall D

The radar needs all six factors. Available grades are shown below.

Valuation B-

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 3.6x Better than 98%
Price / Sales 3.5x Better than 36%
P/E vs own 5-yr range 90th pctl Better than 15%
Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D-

How much profit the business keeps from each dollar of sales and capital.

Gross margin -19.5% Better than 1%
Operating margin -192.1% Better than 5%
Net margin -237.9% Better than 5%
Return on equity -38.5% Better than 11%
Return on invested capital -42.6% Better than 7%
Momentum C

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -22.8% Better than 26%
6-month return -7.6% Better than 43%
12-month return (ex latest month) -2.6% Better than 31%
Distance below 52-week high 26.2% Better than 48%
Financial Health B+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 15.7x Better than 97%
Debt to assets 0.8% Better than 94%
Interest coverage -344.4x Better than 3%
Free cash flow / net income 111.0% Better than 46%
Analyst View N/A

What the Street thinks: share of Buy ratings and upside to the average target.

Not enough data to grade this factor.

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -1.71%
1M -7.16%
3M -15.72%
6M -8.01%
YTD -16.42%
1Y -4.29%
3Y +118.48%
5Y +21.82%

Key statistics

Price & volume

Prev close
4.07
Open
4.01
Day range
3.97 - 4.09
Avg price
4.04
Volume
2.99M
Turnover
12.08M
Amplitude
2.95%
52-week range
3.50 - 5.45

Valuation

P/E
-23.65
P/E (TTM)
3.59
P/B
7.19
EPS
-0.17
Net profit
-26.06M
Net assets
85.69M

Share structure

Market cap
616.24M
Float cap
457.21M
Shares out
153.29M
Float shares
113.73M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2015-05-04
52-week range 27% of range
3.50 5.45

26.2% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+59.09K net over the window

Short interest

Shares short
19.89M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Arbutus Biopharma (ABUS)?

Arbutus Biopharma last traded at 4.02. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Arbutus Biopharma's market cap?

About 616.24M.

What is the P/E ratio of Arbutus Biopharma?

The trailing twelve-month P/E is 3.59. The Valuation tab shows it against the stock's own five-year range.

Does Arbutus Biopharma pay a dividend?

Arbutus Biopharma does not currently pay a regular dividend.

What is Arbutus Biopharma's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Arbutus Biopharma a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:39:17 · For reference only, not investment advice and not tailored to your situation.

Arbutus Biopharma discussion 0 comments

Add a comment